Clinical Trials Browser

Thoracic × Clear all

NCT01851395 2026-04-22

Rapid Autopsy and Procurement of Cancer Tissue

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Urogenital Neoplasms

NCT03043872 2026-04-22

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT03481114 2026-04-22

REPAINT

Phase 2 Completed

55 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT03563976 2026-04-22

Multiparametric Image Analysis and Correlation With Outcomes in Lung Cancer Screening and Early Stage Lung Cancer

Lung Neoplasms

NCT04267848 2026-04-22

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04487080 2026-04-22

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Phase 2 Active not recruiting

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04826341 2026-04-22

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Phase 1/2 Active not recruiting

Other solid neoplasmThoracic

HRD Cancer

NCT04988295 2026-04-22

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05198830 2026-04-22

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Adenocarcinoma of Lung, Lung Neoplasms

NCT05363319 2026-04-22

CEMI-LUNG

Carcinoma, Non-Small-Cell Lung

NCT05415358 2026-04-22

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05642195 2026-04-22

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Phase 1/2 Suspended

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05687266 2026-04-22

AVANZAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06077760 2026-04-22

INTerpath-002

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06257264 2026-04-22

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06498635 2026-04-22

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06607185 2026-04-22

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06694454 2026-04-22

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06707519 2026-04-22

NSCLC Liquid Biopsies and Exhaled VOC

Lung Neoplasms

NCT06773910 2026-04-22

TIGOS-LS

Phase 2 Recruiting

Limited Stage Small Cell Lung Cancer

NCT06898957 2026-04-22

(DeLLphi-310)

Phase 1 Active not recruiting

Small Cell Lung Carcinoma

NCT06922591 2026-04-22

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Phase 1/2 Recruiting

Lung Neoplasms

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07057791 2026-04-22

PrE0510

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT07085091 2026-04-22

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Phase 1 Recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07099898 2026-04-22

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Phase 3 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07328490 2026-04-22

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

Phase 1/2 Not yet recruiting

Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT07404202 2026-04-22

Pan HER2

Pan-tumor(NSCLC, GYN Cancers, BTC and UC)

NCT07413757 2026-04-22

CHOICE

Carcinoma, Non-Small-Cell Lung

NCT07509034 2026-04-22

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Phase 1 Not yet recruiting

Recurrence, Small Cell Lung Carcinoma

NCT07543601 2026-04-22

ECHELON

Phase NA Recruiting

Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

NCT07545213 2026-04-22

Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07545954 2026-04-22

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

Phase 1 Not yet recruiting

Small Cell Lung Carcinoma

NCT00034216 2026-04-21

Collection of Blood From Patients With Cancer

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

NCT02194738 2026-04-21

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase NA Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02257619 2026-04-21

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03710876 2026-04-21

INFINITE

Phase 3 Completed

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03872661 2026-04-21

NIBCUN

Phase 2 Recruiting

Lung Neoplasms

NCT04147351 2026-04-21

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Phase 2 Completed

NSCLC Stage IIIB~IV

NCT04181060 2026-04-21

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT04183218 2026-04-21

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

24 enrolled 21 charts

Lung Neoplasms

NCT04765059 2026-04-21

COMPEL

Phase 3 Active not recruiting

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT05132075 2026-04-21

KontRASt-02

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05445843 2026-04-21

KontRASt-06

Phase 2 Active not recruiting

95 enrolled 20 charts

Lung Neoplasms

NCT05537740 2026-04-21

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT05732831 2026-04-21

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT06096844 2026-04-21

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Phase 3 Recruiting

Lung Neoplasms